Paul N. Brennan

Effect of COVID-19 on presentations of decompensated liver disease in Scotland

Muhammad Ishaq Khan, K. Simpson, T. Goh, 2022, BMJ open gastroenterology.

Quality Standards for the Management of NAFLD: Consensus Recommendations from the British Association for the Study of the Liver (BASL) and British Society of Gastroenterology (BSG) NAFLD Special Interest Group

R. Goldin, M. Armstrong, E. Tsochatzis, 2022, The lancet. Gastroenterology & hepatology.

Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?

E. Tapper, J. Dillon, Paul N Brennan, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD

J. Dillon, Paul N Brennan, K. Clare, 2022, Journal of clinical and translational hepatology.

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)

J. Fallowfield, S. Forbes, M. Turner, 2021, BMJ Open.

A global research priority agenda to advance public health responses to fatty liver disease.

V. Wong, J. Lazarus, K. Cusi, 2023, Journal of hepatology.

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

C. Byrne, Paul N. Brennan, Marc Gurun, 2024, PLoS ONE.

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis

J. Dillon, R. McCrimmon, Paul N Brennan, 2022, TouchREVIEWS in endocrinology.

A global action agenda for turning the tide on fatty liver disease

V. Wong, J. Lazarus, K. Cusi, 2023, Hepatology.